v3.26.1
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Net revenues $ 4,142 $ 4,176 $ 8,124 $ 8,067
Cost of sales 1,989 2,074 4,000 4,088
Gross profit 2,153 2,102 4,124 3,979
Research and development expenses 970 244 1,191 490
Selling and marketing expenses 717 654 1,413 1,276
General and administrative expenses 317 305 621 603
Intangible assets impairments 22 42 30 163
Other assets impairments, restructuring and other items 147 232 173 210
Legal settlements and loss contingencies 230 166 303 252
Other loss (income) (19) 4 (28) 9
Operating income (loss) (231) 455 421 975
Financial expenses, net 224 252 440 477
Income (loss) before income taxes (455) 203 (18) 497
Income taxes (benefit) 121 (78) 188 (4)
Share in (profits) losses of associated companies, net   (1) 1 [1] (1)
Net income (loss) (575) 283 (206) 503
Net income (loss) attributable to redeemable and non-redeemable non-controlling interests       6
Net income (loss) attributable to Teva $ (576) $ 282 $ (207) $ 497
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ (0.49) $ 0.25 $ (0.18) $ 0.43
Diluted $ (0.49) $ 0.24 $ (0.18) $ 0.43
Weighted average number of shares (in millions):        
Basic 1,165 1,147 1,160 1,142
Diluted 1,165 1,161 1,160 1,159
[1] Represents an amount less than $0.5 million.